Recent Updates
Recently added Catalysts
IDXG Positive Sentiment

Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue

Key Takeaway: Interpace Biosciences anticipates preliminary, unaudited revenue for Q3 2026 to be between $10.1 million and $10.4 million. This represents an 11% to 14% increase from Q2 2026 and a 15% to 18% increase compared to Q3 2025. The final results will be reported after the company's quarter-end closing procedures.
Price reaction · baseline $5.518 (2026-10-14 close) · hit after-hours · clean, no other IDXG news in the window
day 0 close · peak
-4.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Expected revenue range of $10.1M to $10.4M
  • Quarter-over-quarter growth of 11% to 14%
  • Year-over-year growth of 15% to 18%

Full Press Release Details

• Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million
• Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026
• Expected year-over-year growth of approximately 15% to 18% compared with Q3 2025
PARSIPPANY, NJ, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCID: IDXG) today announced that it expects preliminary, unaudited revenue for the third quarter ended September 30, 2026 to range from $10.1 million to $10.4 million.
The expected revenue range represents an increase of approximately 11% to 14% compared with revenue of $9.1 million for the second quarter of 2026 and an increase of approximately 15% to 18% compared with revenue of $8.8 million for the third quarter of 2025.
The estimated revenue presented in this release is preliminary and unaudited, is based on information currently available to management, and remains subject to completion of the Company’s quarter-end closing procedures and review by the Company’s independent registered public accounting firm. Actual results may differ, including materially, from the range presented above. The Company expects to report complete financial results for the third quarter of 2026 at a later date.

About Interpace Biosciences

Interpace Biosciences is an emerging leader in enabling personalized medicine through specialized molecular diagnostic tests and related services. The Company’s commercialized thyroid tests include ThyGeNEXT® and ThyraMIR®v2, which are used together to support the evaluation of indeterminate thyroid nodules. For more information, please visit www.interpace.com.

Free Writing Prospectus

The issuer has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (SEC) for the offering to which this free writing prospectus communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling 612-326-1305. You may also access the registration statement (including the prospectus) through the following link:

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the Company’s expected revenue for the third quarter of 2026 and the timing of its complete financial results. These statements are based on management’s current expectations and information available as of the date of this release and are subject to risks, uncertainties, closing adjustments and other factors that could cause actual results to differ materially. Such factors include those described under “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. The preliminary, unaudited financial information in this release has not been reviewed by the Company’s independent registered public accounting firm and is subject to change as the Company completes its quarter-end closing and review procedures. The Company’s expected revenues for the third quarter of 2026 may not be indicative of the Company’s net income for such period or for full year results. Readers should not place undue reliance on these forward-looking statements. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

Frequently Asked Questions

What is the expected revenue for Q3 2026?

Interpace expects revenue to range from $10.1 million to $10.4 million.

How does Q3 2026 revenue compare to Q2 2026?

The expected growth is approximately 11% to 14% from Q2 2026.

What is the year-over-year growth for Q3 2026?

Year-over-year growth is expected to be 15% to 18% compared to Q3 2025.

When will the complete financial results be reported?

Complete financial results for Q3 2026 will be reported later.

Last updated: Oct 15, 2026